Technical Analysis for BIIB - Biogen Idec Inc.

Grade Last Price % Change Price Change
grade A 310.33 3.27% 9.82
BIIB closed down 1.3 percent on Friday, April 3, 2020, on 65 percent of normal volume. It ran into resistance at its 50 day moving average.
Earnings due: Apr 22
*** please verify all earnings dates ***

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Up
Historical BIIB trend table...

Date Alert Name Type % Chg
50 DMA Resistance Bearish 3.27%
Multiple of Ten Bullish Other 3.27%
50 DMA Resistance Bearish 1.92%
Crossed Above 20 DMA Bullish 1.92%
Pocket Pivot Bullish Swing Setup 1.92%
Multiple of Ten Bullish Other 1.92%
Fell Below 20 DMA Bearish 5.82%
Fell Below 50 DMA Bearish 5.82%
Multiple of Ten Bearish Other 5.82%
Overbought Stochastic Strength 5.82%

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile

Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally. Its marketed products include AVONEX for the treatment of relapsing multiple sclerosis (MS); TYSABRI to treat relapsing MS; RITUXAN for treating relapsed or refractory, CD20-positive, and B-cell Non-Hodgkin's lymphoma (NHL); FUMADERM for the treatment of severe plaque psoriasis in adult patients; and FAMPYRA, an oral compound for the improvement of walking in adult patients with MS with walking disability. The company's products that completed Phase III clinical trials comprise TECFIDERA (BG-12) for MS; Peginterferon beta-1a to prolong the effects and reduce the dosing frequency of interferon beta-1a; and long-lasting Factor VIII and IX product candidates for the treatment of hemophilia. Its products under Phase III clinical trials consist of Daclizumab, a monoclonal antibody in relapsing MS; TYSABRI for secondary progressive MS; and GA101, a monoclonal antibody for chronic lymphocytic leukemia and NHL. The company's Phase II clinical trial products include Anti-LINGO for optic neuritis; STX-100 for idiopathic pulmonary fibrosis; and ANTI-TWAEK for lupus nephritis. The company's Phase I clinical trial products comprise Anti-LINGO for MS; BIIB037 for Alzheimer's disease; Neublastin for neuropathic pain; and Anti-CD40 Ligand for general lupus, as well as Phase 1b/2a clinical trial product includes ISIS-SMNRx for spinal muscular atrophy. It has collaboration agreements with Genentech, Inc.; Elan Pharma International, Ltd; Acorda Therapeutics, Inc.; Portola Pharmaceuticals, Inc.; and Swedish Orphan Biovitrum AB. The company was formerly known as IDEC Pharmaceuticals Corporation and changed its name to Biogen Idec Inc. in November 2003. Biogen Idec Inc. was founded in 1985 and is headquartered in Weston, Massachusetts.
Medicine Biotechnology Pain Immunology Monoclonal Antibodies Alzheimer's Disease Multiple Sclerosis Specialty Drugs Autoimmune Disorders Chronic Lymphocytic Leukemia Neurodegenerative Diseases Immunosuppressants Hemophilia Spinal Muscular Atrophy Idiopathic Pulmonary Fibrosis Treatment Of Hemophilia NHL Lupus Nephritis Clinical Trial Products

Is BIIB a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 374.99
52 Week Low 215.775
Average Volume 2,183,915
200-Day Moving Average 270.13
50-Day Moving Average 306.93
20-Day Moving Average 294.37
10-Day Moving Average 296.28
Average True Range 19.55
ADX 14.17
+DI 18.24
-DI 18.61
Chandelier Exit (Long, 3 ATRs ) 267.79
Chandelier Exit (Short, 3 ATRs ) 321.09
Upper Bollinger Band 321.82
Lower Bollinger Band 266.92
Percent B (%b) 0.61
BandWidth 18.65
MACD Line -1.50
MACD Signal Line -3.64
MACD Histogram 2.1308
Fundamentals Value
Market Cap 63.54 Billion
Num Shares 211 Million
EPS 15.24
Price-to-Earnings (P/E) Ratio 19.72
Price-to-Sales 5.55
Price-to-Book 5.61
PEG Ratio 2.22
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 322.59
Resistance 3 (R3) 323.81 317.66 318.91
Resistance 2 (R2) 317.66 312.04 317.06 317.68
Resistance 1 (R1) 309.09 308.57 306.02 307.87 316.46
Pivot Point 302.94 302.94 301.41 302.34 302.94
Support 1 (S1) 294.37 297.32 291.30 293.15 284.56
Support 2 (S2) 288.22 293.85 287.62 283.34
Support 3 (S3) 279.65 288.22 282.11
Support 4 (S4) 278.43